Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 100

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 100
---
 in protection of our IP rights including patent 
 rights of other parties;                                    |

| ● | the burden of complying with a variety of foreign laws including 
 difficulties in effective enforcement of contractual provisions; |

| ● | delays resulting from difficulty in obtaining export licenses,                                                                       
 tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collection 
 and potentially adverse tax treatment; and                                                                                           |

| ● | production shortages resulting from any events affecting raw 
 material supply or manufacturing capabilities abroad.        |

In addition, we are subject to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes in diplomatic and trade relationships, which could affect, among other things, customers’ inventory levels and consumer purchasing, which could cause our results to fluctuate and our net sales to decline. The occurrence of any one or more of these risks of doing business internationally, individually or in the aggregate, could materially and adversely affect our business and results of operations. If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, IP rights, technology or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to:

| ● | increase in operating expenses and cash requirements; |

| ● | the assumption of additional indebtedness or contingent liabilities; |

| ● | the issuance of our equity securities; |

| ● | assimilation of operations, IP and products of an acquired company, 
 including difficulties associated with integrating new personnel;   |

| ● | the diversion of our management’s attention from our existing                        
 product programs and initiatives in pursuing such a strategic merger or acquisition; |

| ● | retention of key employees, the loss of key personnel, and uncertainties 
 in our ability to maintain key business relationships;                   |

| ● | risks and uncertainties associated with the other party to such                                                                            
 a transaction, including the prospects of that party and their existing drugs or drug and diagnostics technology candidates and regulatory 
 approvals; and                                                                                                                             |

55

| ● | our inability to generate revenue from acquired technology and/or                                                                      
 products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance 
 costs.                                                                                                                                 |

In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire